Guerbet Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Villepinte France (1926)

Organization Overview

First Clinical Trial
2006
NCT00447889
First Marketed Drug
1954
ethiodized oil (ethiodol)
First NDA Approval
1995
ioxilan (oxilan)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Guerbet | GUERBET

Indications

Approved Indications


 

Contrast Media

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arterial Occlusive Diseases (Phase 4)

Arteriovenous Malformations (Phase 4)

Atherosclerosis (Phase 4)

Brain Neoplasms (Phase 4)

Breast Diseases (Phase 1)

Breast Neoplasms (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 4)

Central Nervous System Diseases (Phase 3)

Cerebral Arterial Diseases (Phase 3)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Fibroadenoma (Phase 1)

Hemangioendothelioma (Phase 4)

Hemangioma (Phase 4)

Hemangiosarcoma (Phase 4)

Infertility (Phase 4)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 2)

Liver Neoplasms (Phase 2)

Meniere Disease (Phase 4)

Myocardial Ischemia (Phase 4)

Nervous System Diseases (Phase 3)

Peripheral Arterial Disease (Phase 4)

Peripheral Vascular Diseases (Phase 4)

Renal Artery Obstruction (Phase 3)

Renal Insufficiency (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 37
  • # of Trial APIs: 21